Last reviewed · How we verify
Diflupyl (fluostigmine)
At a glance
| Generic name | fluostigmine |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | fluostigmine |
| Target | Lysosomal protective protein, Acetylcholinesterase, Prostaglandin G/H synthase 2 |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
Common side effects
Key clinical trials
- Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis (PHASE2,PHASE3)
- Study of Parkinson's Early Stage With Deferiprone (PHASE2)
- Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients (PHASE3)
- Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration (PHASE3)
- Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) (PHASE3)
- Pharmacokinetic Study of Deferiprone in Paediatric Patients (PHASE2)
- Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects (PHASE1)
- A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diflupyl CI brief — competitive landscape report
- Diflupyl updates RSS · CI watch RSS
- Merck & Co. portfolio CI